ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) Short Interest Up 644.1% in June
ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) Short Interest Up 644.1% in June
ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS – Get Rating) saw a large increase in short interest during the month of June. As of June 30th, there was short interest totalling 87,800 shares, an increase of 644.1% from the June 15th total of 11,800 shares. Based on an average daily volume of 25,500 shares, the short-interest ratio is presently 3.4 days.
ProShares UltraShort納斯達克生物科技(納斯達克：BIS-GET評級)在6月份見證了空頭股數的大幅增長。截至6月30日，空頭股數共有87,800股，比6月15日的11,800股增加了644.1%。以日均成交量25,500股計算，目前短息比率為3.4天。
Shares of NASDAQ BIS remained flat at $$24.12 during mid-day trading on Thursday. 4,231 shares of the company were exchanged, compared to its average volume of 25,067. The stock has a 50-day simple moving average of $28.76 and a 200 day simple moving average of $26.34. ProShares UltraShort Nasdaq Biotechnology has a 1 year low of $15.86 and a 1 year high of $35.64.
在週四午盤交易中，納斯達克的股價持平於24.12美元。該公司的股票成交量為4231股，而其平均成交量為25067股。該股的50日簡單移動均線切入位為28.76美元，200日簡單移動均線切入位為26.34美元。ProShares UltraShort納斯達克生物科技的一年低點為15.86美元，一年高位為35.64美元。
Several hedge funds and other institutional investors have recently bought and sold shares of BIS. IMC Chicago LLC purchased a new position in shares of ProShares UltraShort Nasdaq Biotechnology in the 1st quarter valued at $450,000. OLD Mission Capital LLC purchased a new position in shares of ProShares UltraShort Nasdaq Biotechnology in the 4th quarter valued at $266,000. Finally, UBS Group AG grew its position in shares of ProShares UltraShort Nasdaq Biotechnology by 54.7% in the 1st quarter. UBS Group AG now owns 1,371 shares of the company's stock valued at $33,000 after buying an additional 485 shares during the last quarter.
幾家對衝基金和其他機構投資者最近買賣了國際清算銀行的股票。IMC芝加哥有限責任公司在第一季度購買了ProShares UltraShort納斯達克生物技術公司新持有的股票，價值45萬美元。舊任務資本有限責任公司在第四季度購買了ProShares UltraShort納斯達克生物科技的新頭寸，價值266,000美元。最後，瑞銀集團在第一季度將其在ProShares UltraShort納斯達克生物科技公司的股票頭寸增加了54.7%。瑞銀集團目前持有1,371股該公司股票，價值33,000美元，上一季度又購買了485股。
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks investment results for a single day only, not for longer periods. The Fund seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from twice (200%) the return of the Nasdaq Biotechnology Index (the Index) for that period.
ProShares超納斯達克生物科技(基金)只尋求一天的投資結果，不尋求較長時期的投資結果。基金尋求扣除費用和費用前的每日投資結果，相當於該指數每日業績的兩倍(200%)。超過一個交易日的基金回報將是這段時間內每一天的回報的複合結果，這很可能與同期納斯達克生物技術指數(該指數)的回報兩倍(200%)不同。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on ProShares UltraShort Nasdaq Biotechnology (BIS)
- Fastenal Stock By the Numbers
- 3 More Stocks For the Second Half to Consider
- United Natural Foods Stock is Ready to be Snacked On
- Elastic Stock is a Buoyant Search Play
- 3M (NYSE: MMM) Is Now A Good Time To Buy 3M After Downgrades?
- 免費獲取StockNews.com關於ProShares UltraShort納斯達克生物技術的研究報告
- Fastenal股票的數字
- 下半年將再考慮3只股票
- 聯合天然食品庫存準備好被點心
- 彈性股票是一種活躍的搜索業務
- 3M(紐約證券交易所代碼：MMM)評級下調後，現在是買入3M的好時機嗎？
Receive News & Ratings for ProShares UltraShort Nasdaq Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares UltraShort Nasdaq Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
獲得ProShares UltraShort納斯達克生物科技日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對ProShares UltraShort納斯達克生物技術和相關公司的最新新聞和分析師評級的每日摘要。
譯文內容由第三人軟體翻譯。